Spectral AI, Inc. Class A (MDAI)

Over the past six months, Spectral AI's stock has been impacted by several events. The company received $31.7 million in BARDA funding, causing shares to surge by 35%. Vincent S. Capone was appointed as CEO. MDAI reported earnings of $0.02 per share, surprising estimates by 115.79%, but R&D revenue dropped 50% due to reduced BARDA contract reimbursements. The company submitted the DeepView® System to the FDA for market authorization, with approval expected by the end of Q2 2026. Analysts have a bullish consensus with a median price target of $5.00. The stock price has seen significant movement, with a 50% jump in the last month and a 92.17% increase over the past year.

The provided search results do not contain explicit information about the demand seasonality for Spectral AI, Inc.'s products and services. Demand is likely driven by the incidence of medical conditions like burns and diabetic foot ulcers, healthcare budgets, and regulatory approvals rather than traditional seasonal consumer patterns. Government contracts also influence demand.

Spectral AI, Inc. is a predictive AI company focused on medical diagnostics for wound care, particularly burns and diabetic foot ulcers. Their core product, the DeepView® System, uses AI and multispectral imaging to assess tissue damage and predict healing potential. They are also developing the DeepView SnapShot® M for use in emergency and home healthcare settings.

Spectral AI is headquartered in Dallas, Texas. They have UKCA mark approval for their DeepView AI-Burn system, with initial revenues expected from the UK. They are planning global expansion with clinical trials in Australian burn centers and anticipated commercialization in Europe. A De Novo application was submitted to the FDA in June 2025, with approval expected by the end of Q2 2026.

Spectral AI has garnered positive recognition in the past year. They were named to TIME's World's Top HealthTech Companies 2025 list. Spectral AI received the Small Business Innovator Award at the Texas Innovation Conference for its DeepView® System. The DeepView® System was showcased at the 2026 American Burn Association Annual Meeting, where clinicians presented positive findings on its accuracy and usability.

Spectral AI, Inc. has a mixed ownership structure. Approximately 9.61% of the company's stock is owned by institutional investors, including Hudson Bay Capital Management LP and The Vanguard Group, Inc. Insiders own approximately 9.56% of the company's stock, with John Michael DiMaio being the largest individual shareholder. Public companies and individual investors own approximately 80.82% of the stock.